AZ recruits ImaginAb in CD8 ImmunoPET deal

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET minibody works by binding CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients.